Teva Receives FDA Approval for DEGEVMA Biosimilar to Xgeva

Key Facts

The U.S. Food and Drug Administration (FDA) approved Teva Pharmaceutical Industries' DEGEVMA as a biosimilar to Xgeva. GlobeNewswire reported that the drug is indicated for preventing bone complications in adults with advanced cancer that has spread to the bone, as well as treating giant cell tumor of bone and hypercalcemia of malignancy.

The approval aligns with the company's strategy to expand its innovative biosimilar portfolio and provide affordable treatment options. According to a company statement, this regulatory milestone supports revenue growth in the specialized medicines segment as the firm continues its organizational transformation and cost-saving initiatives.